193902-86-2

Basic information

• Product Name: TERT-BUTYL 4-(2-METHYL-4-NITROPHENYL)PIPERAZINE-1-CARBOXYLATE
• Synonyms: TERT-BUTYL 4-(2-METHYL-4-NITROPHENYL)PIPERAZINE-1-CARBOXYLATE;tert-butyl 4-(4-nitro-2-(trifluoromethyl)phenyl)piperazine-1-carboxylate;tert-butyl 4-(4-nitro-2-(trifluoromethyl)phenyl)piperazine-1-carboxylate（WS204198）
• CAS NO: 193902-86-2
• Molecular Formula: C₁₆H₂₀F₃N₃O₄
• Molecular Weight: 321.37152
• Mol File: 193902-86-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: TERT-BUTYL 4-(2-METHYL-4-NITROPHENYL)PIPERAZINE-1-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 4-(2-METHYL-4-NITROPHENYL)PIPERAZINE-1-CARBOXYLATE(193902-86-2)
• EPA Substance Registry System: TERT-BUTYL 4-(2-METHYL-4-NITROPHENYL)PIPERAZINE-1-CARBOXYLATE(193902-86-2)

Safety Data

• Hazardous Substances Data: 193902-86-2(Hazardous Substances Data)

Upstream product

• 400-74-8 2-Fluoro-5-nitrobenzotrifluoride 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 777-37-7 4-chloro-3-(trifluoromethyl)nitrobenzene 

Downstream Products

• 381242-61-1 1-[4-nitro-2-(trifluoromethyl)phenyl]piperazine 
• 193902-87-3 tert-butyl 4-(4-amino-2-(trifluoromethyl)phenyl)piperazine-1-carboxylate 

Relevant articles and documents

NOVEL INHIBITORS OF MAP4K1

The invention relates to novel inhibitors of MAP4K1 (HPK1) useful for the treatment of diseases or disorders characterised by dysregulation of the signal transduction pathways associated with MAPK activation, including hyperproliferative diseases, diseases of immune system dysfunction, inflammatory disorders, neurological diseases, and cardiovascular diseases. The invention further relates to pharmaceutical compositions comprising the same and methods of treatment of said diseases and disorders. The inhibitors are of formula (I) wherein the definitions for A, D, E, F, R5, R6, R7, Z, ring Q, n, x and y are as given in the application.

Discovery of novel quinoline-based mTOR inhibitors via introducing intra-molecular hydrogen bonding scaffold (iMHBS): The design, synthesis and biological evaluation

A series of quinoline derivatives featuring the novelty of introducing intra-molecular hydrogen bonding scaffold (iMHBS) were designed, synthesized and biologically evaluated for their mTOR inhibitory activity, as well as anti-proliferative efficacies aga

BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES

Compounds of formula (I) or pharmaceutical acceptable salts are provided, wherein X1~X5, R1~R3, A, B, Z and n are defined in the description. And compositions containing said compounds, and the uses for inhibitors of kinases such as ALK, and the uses for treating cancer thereof are provided.

New 1-aryl-3-substituted propanol derivatives as antimalarial agents

This paper describes the synthesis and in vitro antimalarial activity against a P. falciparum 3D7 strain of some new 1-aryl-3-substituted propanol derivatives. Twelve of the tested compounds showed an IC50 lower than 1 μM. These compounds were

IMIDAZOQUINOLINES AS LIPID KINASE INHIBITORS

The invention relates to novel organic compounds of formula (I) processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof - alone or in combination with one or more other pharmaceutically active compounds - for the treatment of an inflammatory or obstructive airway disease, such as asthma, disorders commonly occurring in connection with transplantation, or a proliferative disease, such as a tumor disease.

Fibrinogen receptor antagonists

This invention relates to compounds of the formula: which are effective for inhibiting platelet aggregation, pharmaceutical compositions for effecting such activity, and a method for inhibiting platelet aggregation.